New study tests Long-Term safety of schizophrenia drug in teens

NCT ID NCT03238326

First seen Feb 04, 2026 · Last updated May 16, 2026 · Updated 17 times

Summary

This study looked at the long-term safety of the drug brexpiprazole in teenagers aged 13 to 17 with schizophrenia. Researchers monitored 295 participants for side effects over time. The goal was to see if the drug is safe enough for ongoing maintenance treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinical Research Site #100

    Rochester, New York, 14618, United States

  • Clinical Research Site #101

    Dothan, Alabama, 36303, United States

  • Clinical Research Site #102

    Oklahoma City, Oklahoma, 73116, United States

  • Clinical Research Site #103

    Long Beach, California, 90807, United States

  • Clinical Research Site #105

    Culver City, California, 90230, United States

  • Clinical Research Site #108

    Everett, Washington, 98201, United States

  • Clinical Research Site #113

    Garfield Heights, Ohio, 44125, United States

  • Clinical Research Site #121

    Kinston, North Carolina, 28501, United States

  • Clinical Research Site #124

    Las Vegas, Nevada, 89109, United States

  • Clinical Research Site #128

    Anaheim, California, 92805, United States

  • Clinical Research Site #130

    New York, New York, 10036, United States

  • Clinical Research Site #133

    Cincinnati, Ohio, 45219, United States

  • Clinical Research Site #135

    Tulsa, Oklahoma, 74136, United States

  • Clinical Research Site #136

    Atlanta, Georgia, 30331, United States

  • Clinical Research Site #138

    Lake Charles, Louisiana, 70629, United States

  • Clinical Research Site #140

    Frisco, Texas, 75034, United States

  • Clinical Research Site #148

    Kansas City, Kansas, 66160, United States

  • Clinical Research Site #160

    Monterrey, Nuevo León, 64710, Mexico

  • Clinical Research Site #161

    Culiacán, Sinaloa, 80230, Mexico

  • Clinical Research Site #163

    León, Guanajuato, 37000, Mexico

  • Clinical Research Site #165

    Guadalajara, Jalisco, 44100, Mexico

  • Clinical Research Site #166

    Mérida, Yucatán, 97070, Mexico

  • Clinical Research Site #168

    Durango, 34000, Mexico

  • Clinical Research Site #170

    San Luis Potosí City, San Luis Potosí, 78213, Mexico

  • Clinical Research Site #171

    Monterrey, Nuevo León, 64310, Mexico

  • Clinical Research Site #224

    Torremolinos, Malaga, 29620, Spain

  • Clinical Research Site #241

    Cluj-Napoca, 400660, Romania

  • Clinical Research Site #242

    Timișoara, 300329, Romania

  • Clinical Research Site #243

    Iași, IS700282, Romania

  • Clinical Research Site #244

    Bucharest, 041914, Romania

  • Clinical Research Site #260

    Poznan, 60-744, Poland

  • Clinical Research Site #263

    Tyniec Mały, Dolnyslask, 55-040, Poland

  • Clinical Research Site #266

    Bialystok, Podlaskie Voivodeship, 15-879, Poland

  • Clinical Research Site #267

    Wroclaw, 54-617, Poland

  • Clinical Research Site #269

    Gdansk, Polorskie, 80-542, Poland

  • Clinical Research Site #270

    Wałbrzych, 58-309, Poland

  • Clinical Research Site #272

    Poznan, 61-485, Poland

  • Clinical Research Site #283

    Naples, 80131, Italy

  • Clinical Research Site #321

    Nice, 06200, France

  • Clinical Research Site #500

    Belgrade, 11000, Serbia

  • Clinical Research Site #501

    Novi Sad, 21000, Serbia

  • Clinical Research Site #502

    Niš, 18000, Serbia

  • Clinical Research Site #503

    Kragujevac, 34000, Serbia

  • Clinical Research Site #504

    Belgrade, 11000, Serbia

  • Clinical Research Site #520

    Lviv, 79021, Ukraine

  • Clinical Research Site #521

    Kharkiv, 61153, Ukraine

  • Clinical Research Site #522

    Kherson, 73488, Ukraine

  • Clinical Research Site #523

    Kharkiv, 61068, Ukraine

  • Clinical Research Site #525

    Ternopil, 46027, Ukraine

  • Clinical Research Site #526

    Poltava, Poltava Oblast, 36013, Ukraine

  • Clinical Research Site #527

    Dnipro, 49027, Ukraine

  • Clinical Research Site #540

    Saint Petersburg, 197341, Russia

  • Clinical Research Site #541

    Saint Petersburg, 192019, Russia

  • Clinical Research Site #542

    Arkhangelsk, Primorsky District, 163530, Russia

  • Clinical Research Site #543

    Stavropol, Stavropolskiy Kray, 355038, Russia

  • Clinical Research Site #544

    Yaroslavl, 150003, Russia

  • Clinical Research Site #545

    Moscow, 127083, Russia

Conditions

Explore the condition pages connected to this study.